Ranbaxy Australia Pty Ltd has
said it did not lodge a complaint
with the Australian Competition
and Consumer Commission (ACCC)
about Pfizer.
The company said reports on
the ACCC’s case against Pfizer for
alleged anti-competitive activities
(PD 14 Feb) had suggested it
resulted from a Ranbaxy complaint,
but this was incorrect.
“At the request of the ACCC,
RAPL has provided information in
regards to our company’s launch
and on-going promotion of Trovas
(atorvastatin).”The above article was sent to subscribers in Pharmacy Daily's issue from 24 Feb 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Feb 14
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.